NDA 206494 · Abbvie
Avycaz
Avibactam Sodium, Ceftazidime · Intravenous
NovelPriority reviewLast checked: Nov 20, 2026Latest source record: Apr 25, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2015
Feb 25, 2015
Approved uses
8
Original approval plus efficacy supplements
Registered trials
64
17 Phase 3, 13 recruiting
FAERS reports
169
72 serious, 16 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Apr 30, 2025.
AVYCAZ is a combination of ceftazidime, a cephalosporin, and avibactam, a beta-lactamase inhibitor, indicated for the treatment of the following infections caused by designated susceptible Gram-negative microorganisms in adult and pediatric patients (at least 31 weeks gestational age): Complicated Intra-abdominal Infections (cIAI), used in combination with metronidazole ( 1.1 ) Complicated Urinary Tract Infections (cUTI), including Pyelonephritis ( 1.2 ) Hospital-acquired Bacterial Pneumonia and Ventilator-associated Bacterial Pneumonia (HABP/VABP) ( 1.3 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of AVYCAZ and other antibacterial drugs, AVYCAZ should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. ( 1.4 ) 1. 1 Complicated Intra- a bdominal Infections ( cIAI ) AVYCAZ (ceftazidime and avibactam) in combination with metronidazole, is indicated for the treatment of complicated intra-abdominal infections (cIAI) in adult and pediatric patients (at least 31 weeks gestational age) caused by the following susceptible gram-negative microorganisms: Escherichia coli , Klebsiella pneumoniae , Proteus mirabilis, Enterobacter cloacae, Klebsiella oxytoca, Citrobacter freundii complex, and Pseudomonas aeruginosa . 1. 2 Complicated Urinary Tract Infections ( cUTI ), including Pyelonephritis AVYCAZ (ceftazidime and avibactam) is indicated for the treatment of complicated urinary tract infections (cUTI) including pyelonephritis in adult and pediatric patients (at least 31 weeks gestational age) caused by the following susceptible gram-negative microorganisms: Escherichia coli , Klebsiella pneumoniae, Enterobacter cloacae, Citrobacter freundii complex, Proteus mirabilis , and...
Mechanism: AVYCAZ is an antibacterial drug [ see Clinical Pharmacology ( 12.4 ) ].
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jan 26, 2024 Supplement 12 · Efficacy · priority review LabelLetter
- Dec 20, 2022 Supplement 11 · Efficacy · priority review LabelLetter
- Mar 14, 2019 Supplement 6 · Efficacy · priority review LabelLetter
- Mar 14, 2019 Supplement 5 · Efficacy · priority review LabelLetterPediatric Medical Review
- Feb 1, 2018 Supplement 4 · Efficacy · priority review LabelLetter
- Jan 26, 2017 Supplement 3 · Efficacy · priority review LabelLetter
- Jun 22, 2016 Supplement 2 · Efficacy · priority review LabelLetter
- Feb 25, 2015 Original approval · Type 1 - New Molecular Entity and Type 4 - New Combination · priority review NovelLabelReviewSummary Review
1 products under this application
- AVYCAZ · AVIBACTAM SODIUM EQ 0.5GM BASE; CEFTAZIDIME 2GM/VIAL · POWDER, INTRAVENOUS · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Avibactam" as an intervention, any sponsor and status, largest first.
- A Multicenter Clinical Study on the Continuous vs. Intermittent Infusion of Ceftazidime-Avibactam in Critically Ill Patients With Severe InfectionsPivotal-lookingNot yet recruiting
Southeast University, ChinaAcademic, hospital or other
NCT06939829 · 1,200 participants (planned) · Start May 1, 2025 · Primary completion Dec 31, 2027
Drug: treatment with CAZ-AVI · For: Patients With Critically Ill Infections
- A Study Comparing Ceftazidime-Avibactam Versus Meropenem in Hospitalized Adults With Nosocomial PneumoniaPivotal-lookingCompleted
PfizerPfizer (PFE)
NCT01808092 · 969 participants · Start Apr 2013 · Primary completion Jan 2016
Drug: ceftazidim-avibactam (CAZ-AVI, experimental product); meropenem (active comparator) · For: Nosocomial Pneumonia (NP); Ventilator-associated Pneumonia (VAP)
Sites: Buenos Aires, Argentina; Córdoba, Argentina; Florida, Argentina · 123 sites in all
- Study to Assess the Efficacy and Safety of Meropenem and Pralurbactam in CIAIPivotal-lookingNot yet recruiting
Qilu Pharmaceutical Co., Ltd.Industry
NCT06633718 · 786 participants (planned) · Start Oct 31, 2024 · Primary completion May 30, 2027
Drug: Meropenem and Pralurbactam; Saline and 2 more · For: Intra-abdominal Infections
Sites: Hangzhou, China
- Ceftazidime-Avibactam Compared With Doripenem Followed by Oral Therapy for Hospitalized Adults With Complicated UTIs (Urinary Tract Infections)Pivotal-lookingCompleted
PfizerPfizer (PFE)
NCT01599806 · 641 participants · Start Oct 2012 · Primary completion Aug 2014
Drug: Ceftazidime - Avibactam ( CAZ-AVI); Doripenem and 2 more · For: Complicated Urinary Tract Infection (cUTI) Including Acute Pyelonephritis
Sites: Detroit, Michigan; St Louis, Missouri; Indiana, Pennsylvania · 57 sites in all
- Optimising TREATment for Severe Gram-Negative Bacterial InfectionsPivotal-lookingRecruiting
National University of SingaporeAcademic, hospital or other
NCT07004049 · 600 participants (planned) · Start Apr 21, 2025 · Primary completion Dec 31, 2028
Drug: Colistin/Polymyxin B + Sulbactam; Colistin/Polymyxin B + Tigecycline/Eravacycline and 12 more · For: Bloodstream Infection; Ventilator Associated Bacterial Pneumonia; Hospital Acquired Bacterial Pneumonia and 2 more
Sites: Brisbane, Australia; Hangzhou, China; Xi'an, China · 41 sites in all
- Ceftazidime-Avibactam Compared With Doripenem Followed by Oral Therapy for Hospitalized Adults With Complicated UTIs (Urinary Tract Infections)Pivotal-lookingCompleted
PfizerPfizer (PFE)
NCT01595438 · 598 participants · Start Oct 2012 · Primary completion Aug 2014
Drug: Ceftazidime - Avibactam ( CAZ-AVI); Doripenem and 2 more · For: Complicated Urinary Tract Infection (cUTI) Including Acute Pyelonephritis
Sites: Sylmar, California; Royal Oak, Michigan; Lima, Ohio · 80 sites in all
- A Clinical Study of YK-1169 Versus Ceftazidime-Avibactam in Adults With Hospital-Acquired or Ventilator-Associated Bacterial PneumoniaPivotal-lookingNot yet recruiting
Nanjing Yoko Biomedical Co., Ltd.Industry
NCT07634198 · 590 participants (planned) · Start Jun 4, 2026 · Primary completion Apr 1, 2028
Drug: YK-1169; Ceftazidime-avibactam Injection · For: Hospital-acquired Bacterial Pneumonia (HABP); Ventilator-associated Bacterial Pneumonia (VABP)
- Compare Ceftazidime-Avibactam + Metronidazole Versus Meropenem for Hospitalized Adults With Complicated Intra-Abdominal InfectionsPivotal-lookingCompleted
PfizerPfizer (PFE)
NCT01499290 · 493 participants · Start Mar 2012 · Primary completion Apr 2014
Drug: CAZ-AVI; Metronidazole and 1 more · For: Complicated Intra-Abdominal Infection
Sites: Chula Vista, California; San Diego, California; St Louis, Missouri · 56 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- off label use34
- product storage error15
- drug resistance12
- respiratory failure9
- acute kidney injury8
- hypotension7
- mental status changes7
- pyrexia7
- death6
- dyspnoea6
- headache6
- nausea6
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2015 | 15 |
| 2016 | 22 |
| 2017 | 19 |
| 2018 | 11 |
| 2019 | 26 |
| 2020 | 14 |
| 2021 | 11 |
| 2022 | 10 |
| 2023 | 4 |
| 2024 | 8 |
| 2025 | 14 |
| 2026 | 15 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Avycaz (Ceftazidime/Avibactam)
2024 spending
$19.5M
Beneficiaries
1,123
4,263 claims
Per beneficiary
$17,394
$64.78 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $6,452,941 |
| 2021 | $15,488,474 |
| 2022 | $12,650,710 |
| 2023 | $15,574,943 |
| 2024 | $19,533,400 |
Part B: Avycaz (Ceftazidime/Avibactam) · HCPCS J0714
2024 spending
$303K
Beneficiaries
87
351 claims
Per beneficiary
$3,485
2024 ASP limit $97.92 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $745,400 |
| 2021 | $1,393,971 |
| 2022 | $498,950 |
| 2023 | $255,004 |
| 2024 | $303,195 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Aztreonam-avibactam versus meropenem for the treatment of serious infections caused by Gram-negative bacteria (REVISIT): a descriptive, multinational, open-label, phase 3, randomised trial.
Carmeli Y, Cisneros JM, Paul M, et al. · Lancet Infect Dis 2025 · Clinical Trial, Phase III, Comparative Study
- Population pharmacokinetic/pharmacodynamic modeling to optimize aztreonam-avibactam dose regimens for adult patients.
Xie R, Rogers H, Chow JW, et al. · Antimicrob Agents Chemother 2025 · Clinical Trial, Phase III, Multicenter Study
- Global trends of ceftazidime-avibactam resistance in gram-negative bacteria: systematic review and meta-analysis.
Wang Y, Sholeh M, Yang L, et al. · Antimicrob Resist Infect Control 2025 · Systematic Review, Meta-Analysis
- Systematic review and meta-analysis of in vitro efficacy of antibiotic combination therapy against carbapenem-resistant Gram-negative bacilli.
Scudeller L, Righi E, Chiamenti M, et al. · Int J Antimicrob Agents 2021 · Systematic Review, Network Meta-Analysis
- Efficacy of treatment options for complicated urinary tract infections including acute pyelonephritis: a systematic literature review and network meta-analysis.
Wagenlehner F, Caballero VR, Maheshwari V, et al. · J Comp Eff Res 2025 · Systematic Review, Network Meta-Analysis
- Ceftazidime-avibactam and aztreonam combination for Carbapenem-resistant Enterobacterales bloodstream infections with presumed Metallo-β-lactamase production: a systematic review and meta-analysis.
Gupta N, Boodman C, Prayag P, et al. · Expert Rev Anti Infect Ther 2024 · Systematic Review, Meta-Analysis
Sponsor: AbbVie
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.